Commercializing cell and gene therapies efficiently requires timely decisions about whether to engage a CDMO or develop internal manufacturing capacity. Sometimes the best solution is to do both.
Read MoreBrita Salzmann, EIT
Process Engineer
Los Angeles, CA
Brita Salzmann is a process engineer at CRB with over six years of experience on projects across the United States. Brita is continuing to build her resume with new and exciting projects with a heavy focus in the cell and gene therapy realm, including autologous cell therapy, allogenic cell therapy, somatic stem cells, and viral vectors. Her work has provided our clients with insight on how to better use resources to improve efficiency and works on a wide variety of projects, designing and optimizing bio-manufacturing facilities.
“The best part of my career is knowing that, in some capacity, I am contributing towards improving and potentially saving patient’s lives. There isn’t anything more powerful or rewarding than doing something to better someone’s life. I love hearing about the therapies that our clients are working on and the lives they have impacted.”
Brita has been published in Bioprocess International, Pharmaceutical Engineering magazine, iSpeak’s blog for ISPE, and CRB Cell and Gene Therapy Horizons report. The current rise in cell and gene therapies and her growing knowledge has provided Brita the opportunity to showcase her ability to deliver value through creative design options.
Brita graduated from the University of Colorado at Boulder with a degree in Chemical and Biological Engineering and a minor in Business.